Vascular Medicine News

Icosapent ethyl significantly reduced coronary events and led to numerically fewer CV events at 5 years for patients with CAD and low plasma eicosapentaenoic acid already taking statin therapy, researchers reported.

In patients with obesity and obstructive sleep apnea, those who had weight-loss surgery had approximately 40% reduced risk for major adverse CV events and death compared with those who did not, according to the results of the MOSAIC study.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

Hypertension expert and longtime editorial board member for Healio | Cardiology and Healio | Endocrinology George L. Bakris, MD, died June 15, 2024, at the age of 72.

Elixir Medical announced its novel sirolimus-eluting coronary implant adaptable to vessel physiology was granted a breakthrough device designation by the FDA.

Reflecting disparities in cardiovascular care, there were nearly 800,000 excess CV deaths among Black Americans between 2000 and 2022, according to a “report card” published in the Journal of the American College of Cardiology.

Air pollution exposure may contribute to both CV and cancer risk by interacting with various common risk factors such as inflammation, oxidative stress and epigenetic modifications, according to a state-of-the-art review.

Royal Philips announced the FDA 510(k) clearance and launch of image-guided therapy mobile C-arm system designed for complex vascular needs and clinical procedures such as cardiac interventions, pain management and urology.

Teleflex and its subsidiary Arrow International issued a recall of its intra-aortic balloon catheter kits due to a manufacturing error that may cause the balloon to become overtwisted.

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.